FeesSafety
Pluang+

First Northwest Bancorp reports Q3 2026 net loss of $743K amid credit loss provisions and legal settlement.

Company Fundamentals
29 Oct 2026, 14:00 WIB
GlobeNewsWire
View Source
Bearish
First Northwest Bancorp reports Q3 2026 net loss of $743K amid credit loss provisions and legal settlement.

First Northwest Bancorp reported a net loss of $743,000 for Q3 2026, down from net income in prior quarters due to higher credit loss provisions and a $1.3 million legal settlement expense. Despite the loss, the bank saw growth in customer deposits, a slight increase in net interest margin to 2.96%, and improved asset quality with declining nonperforming loans. The company maintains a strong capital position and is focused on strategic initiatives to enhance profitability and shareholder value going forward.

First Northwest Bancorp's Q3 2026 results provide context for financial sector activity. For readers following financial stocks, 94 of 142 US financial stocks on Pluang rose while 43 fell. Notable movers as of Oct 29, 2026 17:53 WIB include BBVA at USD 23.78 with a -4.92% change and 100% buy order activity, OWL at USD 10.05 up 3.93%, and GLXY at USD 18.35 down 3.88%.

More News

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...

Market News
Bullish
1 hour ago
Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...

Company Fundamentals
Bullish
1 hour ago
Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...

Others
Bullish
2 hours ago
Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...

Market News
Neutral
2 hours ago
Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...

Company Fundamentals
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App